Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Medicilon's News information
News information
Medicilon Events Featured Stories Market Events Videos A.C.E.
Home News Medicilon Events

Congratualtions to Bio-Thera on obtaining NMPA’s approval of clinical trials of BAT1308

2020-06-04
|
Page View：

Congratualtions to Medicilon’s partner, Bio-Thera, on obtaining NMPA’s approval of clinical trials of BAT1308.

On May 27th, 2020, Bio-Thera Solutions, Ltd, annouced the approval of clinical trials on BAT 1308, an anti PD-1 monoclonal antibody.
Medicilon participated in BAT 1308’s preclinical study by conducting the In Vivo PK test and safety evaluation tests under GLP.

Related Articles

In Vitro Evaluation of Antibodies
Targeting IL-23, Medicilon Assists the Development of a Variety of New Drugs for Psoriasis

MedicilonBio-TheraNMPABAT1308In-Vivo-PK
Share：
Return
Relevant newsRelevant news
Medicilon's Drug Discovery services: Chemical and Biological Services
2022-03-24
Medicilon will participate 2018 BIO International Conference
2018-05-16
The 2018 BIO International Conference (BIO) will take place in Boston, MA from June 4-7.  The BIO attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new
Medicilon will participate CBA Annual Meeting 2018
2018-09-21
The CBA Annual Meeting will take place in Foster City, CA on Oct 6, 2018.  The Chinese Bioscience Association (CBA) is a non-profit organization founded in the San Francisco Bay area in 1997. Its mission
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->